Trials / Completed
CompletedNCT01335347
Safety Study of an Oral Vaccine to Prevent Avian Influenza
A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Vaxart · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ND1.1 | adenovirus with the dsRNA adjuvant, dried and put into capsules |
| BIOLOGICAL | Placebo control | Capsules of the same size and shape as experimental groups |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-08-01
- Completion
- 2012-09-01
- First posted
- 2011-04-14
- Last updated
- 2013-01-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01335347. Inclusion in this directory is not an endorsement.